Tezepelumab can Restore Normal Lung Function in Patients with Severe, Uncontrolled Asthma: Pooled Results from the PATHWAY and NAVIGATOR Studies.
Pavord ID. et al, (2025), Pulmonary therapy
Cough Reflex Hypersensitivity: A Common and Important Treatable Trait.
Pavord ID. and Gibson PG., (2025), The journal of allergy and clinical immunology. In practice, 13, 499 - 500
Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment
Lavoie G. et al, (2025), Thorax, 80, 113 - 116
Treatable Traits in Patients with Obstructive Lung Diseases in a Well-Established Asthma/COPD Service for Primary Care.
Dijk L. et al, (2025), International journal of chronic obstructive pulmonary disease, 20, 1189 - 1201
Effects of azithromycin in severe eosinophilic asthma with concomitant monoclonal antibody treatment.
Lavoie G. et al, (2024), Thorax
Biologics in Asthma: Role of Biomarkers.
Lavoie G. and Pavord ID., (2024), Immunology and allergy clinics of North America, 44, 709 - 723
Dupilumab Induces Long-Term On-Treatment Clinical Remission in Patients With Type 2 Asthma.
Pavord ID. et al, (2024), The journal of allergy and clinical immunology. In practice
IL-5 antagonism reverses priming and activation of eosinophils in severe eosinophilic asthma.
Luo J. et al, (2024), Mucosal immunology, 17, 524 - 536
Navigating uncertainty: asthma biologics during pregnancy.
Howell I. et al, (2024), The Lancet. Respiratory medicine
A Simulation Study of the Effect of Clinical Characteristics and Treatment Choice on Reliever Medication Use, Symptom Control and Exacerbation Risk in Moderate-Severe Asthma.
Garcia G. et al, (2024), Advances in therapy
CHARACTERIZATION OF MODERATE AND SEVERE ASTHMA EXACERBATIONS IN THE CAPTAIN STUDY.
Oppenheimer J. et al, (2024), J Allergy Clin Immunol Pract
Blood eosinophils and lung function loss: from passive prediction to active prevention?
Ramakrishnan S. et al, (2024), European Respiratory Journal, 63, 2400812 - 2400812
The Rebirth of Lebrikizumab for Airway Disease.
Pavord ID., (2024), J Allergy Clin Immunol Pract, 12, 1225 - 1227
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma.
Papi A. et al, (2024), Respiratory medicine, 224
Dupilumab reduces exacerbations independent of changes in biomarkers in moderate-to-severe asthma.
Pavord ID. et al, (2024), The journal of allergy and clinical immunology. In practice
Effect of Individual Patient Characteristics and Treatment Choices on Reliever Medication Use in Moderate-Severe Asthma: A Poisson Analysis of Randomised Clinical Trials.
van Dijkman SC. et al, (2024), Advances in therapy, 41, 1201 - 1225
The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.
Russell RJ. et al, (2024), The European respiratory journal
Type-2 inflammation: a key treatable trait associated with lung function decline in chronic airways disease
Petousi N. et al, (2024), Thorax